FIELD: biotechnology.
SUBSTANCE: invention relates to nucleic acids coding antigen-binding polypeptide constructs and can be used for recombinant production of antigen-binding polypeptide construct in mammalian cells. Disclosed are sets of polynucleotides for producing an isolated antigen-binding polypeptide structure, wherein the set of polynucleotides codes an antigen-binding polypeptide structure containing at least a first heterodimer which binds a first epitope, and a second heterodimer which binds a second epitope.
EFFECT: invention provides preferential pairing of heavy chains with specific light chains in heterodimeric structures, which provides expression of a bispecific monoclonal antibody (Mab) with negligible or limited mispairing, and minimizes the need to purify desired heterodimers from undesirable or mistakenly coupled products, heterodimers can also exhibit thermal stability comparable to that of heterodimers which do not contain amino acid modifications, and exhibit antigen binding affinity comparable to heterodimers which do not contain amino acid modifications.
22 cl, 19 dwg, 31 tbl, 15 ex
Title | Year | Author | Number |
---|---|---|---|
CONSTRUCTED PAIRS OF HEAVY-LIGHT IMMUNOGLOBULIN CHAINS AND THEIR USE | 2013 |
|
RU2720472C2 |
ANTIGEN-BINDING POLYPEPTIDE CONSTRUCTS CONTAINING KAPPA AND LAMBDA LIGHT CHAINS, AND APPLICATIONS THEREOF | 2016 |
|
RU2824193C2 |
ANTIBODY-LIKE BINDING PROTEINS WITH DOUBLE VARIABLE REGIONS HAVING CROSS-CROSS ORIENTATION OF BINDING REGIONS | 2012 |
|
RU2823693C2 |
METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
Authors
Dates
2024-09-05—Published
2013-11-28—Filed